Last reviewed · How we verify

Indocyanine Green Drug

Theodor Bilharz Research Institute · FDA-approved active Small molecule

Indocyanine Green Drug is a Near-infrared fluorescent contrast agent Small molecule drug developed by Theodor Bilharz Research Institute. It is currently FDA-approved for Ophthalmic angiography and retinal imaging, Intraoperative surgical visualization and tissue perfusion assessment, Cardiac and vascular imaging. Also known as: IC-GREEN, ICG Drug in solution.

Indocyanine Green is a near-infrared fluorescent dye that absorbs and emits light in the near-infrared spectrum for diagnostic imaging and surgical visualization.

Indocyanine Green is a near-infrared fluorescent dye that absorbs and emits light in the near-infrared spectrum for diagnostic imaging and surgical visualization. Used for Ophthalmic angiography and retinal imaging, Intraoperative surgical visualization and tissue perfusion assessment, Cardiac and vascular imaging.

At a glance

Generic nameIndocyanine Green Drug
Also known asIC-GREEN, ICG Drug in solution
SponsorTheodor Bilharz Research Institute
Drug classNear-infrared fluorescent contrast agent
ModalitySmall molecule
Therapeutic areaDiagnostic imaging / Surgery
PhaseFDA-approved

Mechanism of action

Indocyanine Green (ICG) is a tricarbocyanine dye that fluoresces in the near-infrared region (780–820 nm), allowing real-time visualization of blood vessels, tissue perfusion, and anatomical structures during surgical procedures and diagnostic imaging. When excited by near-infrared light, ICG emits fluorescence that penetrates tissue with minimal absorption and autofluorescence, enabling enhanced visualization in ophthalmology, cardiac imaging, and intraoperative guidance.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Indocyanine Green Drug

What is Indocyanine Green Drug?

Indocyanine Green Drug is a Near-infrared fluorescent contrast agent drug developed by Theodor Bilharz Research Institute, indicated for Ophthalmic angiography and retinal imaging, Intraoperative surgical visualization and tissue perfusion assessment, Cardiac and vascular imaging.

How does Indocyanine Green Drug work?

Indocyanine Green is a near-infrared fluorescent dye that absorbs and emits light in the near-infrared spectrum for diagnostic imaging and surgical visualization.

What is Indocyanine Green Drug used for?

Indocyanine Green Drug is indicated for Ophthalmic angiography and retinal imaging, Intraoperative surgical visualization and tissue perfusion assessment, Cardiac and vascular imaging.

Who makes Indocyanine Green Drug?

Indocyanine Green Drug is developed and marketed by Theodor Bilharz Research Institute (see full Theodor Bilharz Research Institute pipeline at /company/theodor-bilharz-research-institute).

Is Indocyanine Green Drug also known as anything else?

Indocyanine Green Drug is also known as IC-GREEN, ICG Drug in solution.

What drug class is Indocyanine Green Drug in?

Indocyanine Green Drug belongs to the Near-infrared fluorescent contrast agent class. See all Near-infrared fluorescent contrast agent drugs at /class/near-infrared-fluorescent-contrast-agent.

What development phase is Indocyanine Green Drug in?

Indocyanine Green Drug is FDA-approved (marketed).

What are the side effects of Indocyanine Green Drug?

Common side effects of Indocyanine Green Drug include Hypersensitivity reactions, Transient nausea, Iodine-related reactions (in iodine-sensitive patients).

Related